ERBB2 and inflammatory breast carcinoma: We found significantly inferior oncological outcomes, including median PFS and OS, with CDKI-based therapy in the metastatic setting for the management of IBC than with those reported in large-scale studies in patients with non-IBC HR+HER2− MBC, suggesting the approval of these agents.